Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 5:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 55 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Low-Dose Naltrexone Clear all
Completed Phase 2 Interventional Results available

The Preventive Treatment of Migraine With Low-Dose Naltrexone and Acetaminophen Combination

NCT03194555
View directory record Official record
Conditions
Migraine With or Without Aura
Interventions
Low-Dose Naltrexone and Acetaminophen Combination, Placebo
Drug
Lead sponsor
Allodynic Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
North Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Oct 19, 2026, 5:33 PM EDT
Recruiting Phase 4 Interventional

Low Dose Naltrexone for Pain in Patients With HIV

NCT05537935
View directory record Official record
Conditions
Human Immunodeficiency Virus, Chronic Neuropathic Pain
Interventions
Low Dose Naltrexone
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 19, 2026, 5:33 PM EDT
Terminated Phase 2 Interventional Results available

Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19

NCT04365985
View directory record Official record
Conditions
COVID-19, Acute Respiratory Distress Syndrome, Severe Acute Respiratory Syndrome (SARS), Coronavirus Infections
Interventions
Naltrexone, Ketamine, Placebo
Drug · Other
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 26, 2022 · Synced Oct 19, 2026, 5:33 PM EDT
Recruiting Phase 2 Interventional

Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)

NCT07224009
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
Naltrexone
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 19, 2026, 5:33 PM EDT
Completed Not applicable Interventional Results available

Effects of Low Dose Naltrexone in Fibromyalgia

NCT00568555
View directory record Official record
Conditions
Fibromyalgia, Persian Gulf Syndrome
Interventions
Low Dose Naltrexone, Placebo - sugar pill
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2015 · Synced Oct 19, 2026, 5:33 PM EDT
Withdrawn Phase 2 Interventional

Single-Site Study of Naltrexone/Acetaminophen for the Acute Treatment of Migraine: A Phase 2 Randomized Trial

NCT05685225
View directory record Official record
Conditions
Migraine
Interventions
Stage 1: Naltrexone/Acetaminophen, Stage 1: Naltrexone, Stage 1: Acetaminophen, Stage1: Placebo, Stage 2: Naltrxone/Acetaminophen high dose, Stage 2: Naltrexone/Acetaminophen medium dose, Stage 2: Naltrxone/Acetaminophen low dose, Stage 2: Placebo
Drug
Lead sponsor
Allodynic Therapeutics, Inc
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
North Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 19, 2026, 5:33 PM EDT
Completed Phase 2 Interventional Results available

Low-Dose Naltrexone (LDN) for Depression Relapse and Recurrence

NCT01874951
View directory record Official record
Conditions
Major Depressive Disorder, Depression, Unipolar, Recurrence, Relapse
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2017 · Synced Oct 19, 2026, 5:33 PM EDT
Completed Phase 2 Interventional Results available

Targeted Interventions for Weight-Concerned Smokers

NCT00105482
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Naltrexone, Transdermal nicotine replacement, Behavioral counseling
Drug · Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 5, 2013 · Synced Oct 19, 2026, 5:33 PM EDT
Recruiting Not applicable Interventional

Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome

NCT02502162
View directory record Official record
Conditions
Complex Regional Pain Syndrome
Interventions
LDN, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 19, 2026, 5:33 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Endogenous Modulation and Central Sensitization in New Daily Persistent Headache ( NDPH ) in Children

NCT03447782
View directory record Official record
Conditions
New Daily Persistent Headache (NDPH)
Interventions
Naltrexone HCl (Bulk) Powder
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
10 Years to 17 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2022 · Synced Oct 19, 2026, 5:33 PM EDT
Completed Not applicable Interventional Results available

Low Dose Naltrexone (LDN) Immune Monitoring

NCT02107014
View directory record Official record
Conditions
Fibromyalgia
Interventions
Low Dose Naltrexone
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 19, 2026, 5:33 PM EDT
Not yet recruiting Phase 4 Interventional

Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1s

NCT07832084
View directory record Official record
Conditions
Obesity & Overweight, Cardiometabolic Health Indicators
Interventions
GLP-1 dose reduction, non-GLP weight loss medication, Maintenance of GLP-1 dose, Resistance exercise regimen, Lifestyle/nutrition counseling
Drug · Behavioral
Lead sponsor
Jing Luo
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 19, 2026, 5:33 PM EDT
Completed Not applicable Interventional Results available

Effect of Naltrexone on Counterregulatory Mechanisms in Hypoglycemia

NCT01462227
View directory record Official record
Conditions
Hypoglycemia
Interventions
Naltrexone High Dose, Naltrexone Low Dose
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 18, 2016 · Synced Oct 19, 2026, 5:33 PM EDT
Completed Phase 2 Interventional

Addition of Naltrexone to Methadone Taper

NCT00135759
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders, Substance-Related Disorders
Interventions
naltrexone, Placebo comparator
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 19, 2026, 5:33 PM EDT
Terminated Phase 3 Interventional Results available

Low-Dose Naltrexone in Combination With Standard Treatment in Women With Endometriosis

NCT03970330
View directory record Official record
Conditions
Endometriosis
Interventions
Naltrexone, Norethindrone Acetate, Placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Oct 19, 2026, 5:33 PM EDT
Terminated Phase 2 Interventional Results available

Low-dose Naltrexone for Bladder Pain Syndrome

NCT04450316
View directory record Official record
Conditions
Bladder Pain Syndrome, Interstitial Cystitis
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 19, 2026, 5:33 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

iSTEP-N 101b: Pharmacokinetics and Safety Study of Low- and High-Dose Naltrexone Implants vs Monthly Vivitrol in Healthy Volunteers

NCT07064564
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Naltrexone implant, 14.4 grams, Naltrexone implant, 9.6 grams, Extended-release naltrexone injection, 380 mg
Drug
Lead sponsor
Akyso Therapeutics, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Millcreek, Utah
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 19, 2026, 5:33 PM EDT
Recruiting Phase 2 Interventional

Low-Dose Naltrexone for the Treatment of Painful Diabetic Neuropathy

NCT04678895
View directory record Official record
Conditions
Painful Diabetic Neuropathy
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 19, 2026, 5:33 PM EDT
Completed Phase 2 Interventional

Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome

NCT04604704
View directory record Official record
Conditions
Covid19, Long COVID-19, Post-COVID-19 Syndrome
Interventions
Naltrexone, NAD+
Drug · Dietary Supplement
Lead sponsor
AgelessRx
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Oct 19, 2026, 5:33 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Combination Gerotherapeutic Interventions for Healthspan Improvement

NCT07475546
View directory record Official record
Conditions
Healthspan Improvement, Aging, Longevity
Interventions
Rapamycin, Naltrexone, Metformin, NAD+, GSH, Infinite Supplement, Placebo/control, B12, Intervention: Guided Meditation Program, Control: Podcast Listening Activity, Control: Standard Exercise Regimen, Intervention: Structured Exercise Program
Drug · Dietary Supplement · Behavioral
Lead sponsor
AgelessRx
Industry
Eligibility
60 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 19, 2026, 5:33 PM EDT
Completed Phase 2 Interventional Results available

Low Dose Naltrexone for Glioma Patients

NCT01303835
View directory record Official record
Conditions
Malignant Glioma
Interventions
LDN, Placebo
Drug
Lead sponsor
Katy Peters
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 17, 2015 · Synced Oct 19, 2026, 5:33 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone

NCT04313972
View directory record Official record
Conditions
Interstitial Cystitis, Painful Bladder Syndrome, Bladder Pain Syndrome, Low Dose Naltrexone, Low-dose Naltrexone, Naltrexone
Interventions
low-dose naltrexone, Placebo oral tablet
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 110 Years · Female only
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Skokie, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 19, 2026, 5:33 PM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT)

NCT07221565
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Autoimmune Diseases, Chronic Inflammatory Syndromes, Immune Dysregulation
Interventions
Low-Frequency Electromagnetic Resonance Therapy (LF-EMR), Sham Resonance Device (Inactive Control), Low-Dose Naltrexone (LDN)
Device · Drug
Lead sponsor
Truway Health, Inc.
Industry
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 19, 2026, 5:33 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Low Dose Naltrexone in Symptomatic Inflammatory Bowel Disease

NCT01810185
View directory record Official record
Conditions
Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
Interventions
Low dose naltrexone, Placebo
Drug
Lead sponsor
Santa Barbara Cottage Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Nov 20, 2014 · Synced Oct 19, 2026, 5:33 PM EDT